{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:12:59Z","timestamp":1769728379372,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,6,15]]},"DOI":"10.1007\/s10637-018-0673-y","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T07:18:13Z","timestamp":1538983093000},"page":"579-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review"],"prefix":"10.1007","volume":"37","author":[{"given":"Hyeon","family":"Cheun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kook-Hwan","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4247","authenticated-orcid":false,"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"key":"673_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"673_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF (2017) Pembrolizumab as second-line therapy for advanced Urothelial carcinoma. N Engl J Med 376:1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"673_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"673_CR4","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL (2017) Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and friends of Cancer research joint research statement. J Clin Oncol Off J Am Soc Clin Oncol 35:3737\u20133744. https:\/\/doi.org\/10.1200\/JCO.2017.73.7916","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"673_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/1759-7714.12641","volume":"9","author":"SH Yoo","year":"2018","unstructured":"Yoo SH, Keam B, Kim M, Kim TM, Kim DW, Heo DS (2018) Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer. Thorac Cancer 9:736\u2013744. https:\/\/doi.org\/10.1111\/1759-7714.12641","journal-title":"Thorac Cancer"},{"key":"673_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2016.12.017","volume":"74","author":"M Donia","year":"1990","unstructured":"Donia M, Kimper-Karl ML, H\u00f8yer KL, Bastholt L, Schmidt H, Svane IM (1990) (2017) the majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. Eur J Cancer Oxf Engl 74:89\u201395. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.017","journal-title":"Eur J Cancer Oxf Engl"},{"key":"673_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/sdi.12371","volume":"28","author":"N Janus","year":"2015","unstructured":"Janus N, Launay-Vacher V (2015) Anticancer drugs in end-stage kidney disease patients. Semin Dial 28:413\u2013416. https:\/\/doi.org\/10.1111\/sdi.12371","journal-title":"Semin Dial"},{"key":"673_CR8","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Liti\u00e8re S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"673_CR9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2215\/CJN.00950208","volume":"3","author":"S Kato","year":"2008","unstructured":"Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B (2008) Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol CJASN 3:1526\u20131533. https:\/\/doi.org\/10.2215\/CJN.00950208","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"673_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD (2017) Pneumonitis in patients treated with anti-programmed Death-1\/programmed death ligand 1 therapy. J Clin Oncol Off J Am Soc Clin Oncol 35:709\u2013717. https:\/\/doi.org\/10.1200\/JCO.2016.68.2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"673_CR11","unstructured":"Opdivo (nivolumab) injection label by FDA (available at https:\/\/www.accessdata.fda.gov)"},{"key":"673_CR12","unstructured":"Yervoy (ipilimumab) injection label by FDA (available at https:\/\/www.accessdata.fda.gov)"},{"key":"673_CR13","unstructured":"Keytruda (pembrolizumab) injection label by FDA (available at https:\/\/www.accessdata.fda.gov)"},{"key":"673_CR14","unstructured":"Tecentriq (atezolizumab) injection label by FDA (available at https:\/\/www.accessdata.fda.gov)"},{"key":"673_CR15","unstructured":"2013-Dialysis-Drugs.pdf (available at https:\/\/homedialyzorsunited.org)"},{"key":"673_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJM198107163050320","volume":"305","author":"H Nakauchi","year":"1981","unstructured":"Nakauchi H, Okumura K, Tango T (1981) Immunoglobulin levels in patients on long-term hemodialysis. N Engl J Med 305:172\u2013173. https:\/\/doi.org\/10.1056\/NEJM198107163050320","journal-title":"N Engl J Med"},{"key":"673_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/ajh.10213","volume":"71","author":"AP Jillella","year":"2002","unstructured":"Jillella AP, Dainer PM, Kallab AM, Ustun C (2002) Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J Hematol 71:219\u2013222. https:\/\/doi.org\/10.1002\/ajh.10213","journal-title":"Am J Hematol"},{"key":"673_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/annonc\/mdv550","volume":"27","author":"S Postel-Vinay","year":"2016","unstructured":"Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A (2016) Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol Off J Eur Soc Med Oncol 27:214\u2013224. https:\/\/doi.org\/10.1093\/annonc\/mdv550","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"673_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Dur\u00e1n I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE III, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Th\u00e5str\u00f6m AC, Abidoye OO, Fine GD, Bajorin DF (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet Lond Engl 389:67\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(16)32455-2","journal-title":"Lancet Lond Engl"},{"key":"673_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","volume":"6","author":"G Bajaj","year":"2017","unstructured":"Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y (2017) Model-based population pharmacokinetic analysis of Nivolumab in patients with solid tumors. CPT Pharmacomet Syst Pharmacol 6:58\u201366. https:\/\/doi.org\/10.1002\/psp4.12143","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"673_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/CMAR.S73389","volume":"7","author":"L Cavalcante","year":"2015","unstructured":"Cavalcante L, Amin A, Lutzky J (2015) Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease. Cancer Manag Res 7:47\u201350. https:\/\/doi.org\/10.2147\/CMAR.S73389","journal-title":"Cancer Manag Res"},{"key":"673_CR22","doi-asserted-by":"publisher","unstructured":"Chang R, Shirai K (2016) Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Rep 2016: pii: bcr2016216426. doi: https:\/\/doi.org\/10.1136\/bcr-2016-216426","DOI":"10.1136\/bcr-2016-216426"},{"key":"673_CR23","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.eururo.2016.05.040","volume":"70","author":"MI Carlo","year":"2016","unstructured":"Carlo MI, Feldman DR (2016) Response to Nivolumab in a patient with metastatic clear cell renal cell carcinoma and end-stage renal disease on Dialysis. Eur Urol 70:1082\u20131083. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.040","journal-title":"Eur Urol"},{"key":"673_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/iju.13420","volume":"24","author":"T Tabei","year":"2017","unstructured":"Tabei T, Natsume I, Kobayashi K (2017) Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment. Int J Urol Off J Jpn Urol Assoc 24:708\u2013710. https:\/\/doi.org\/10.1111\/iju.13420","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"673_CR25","doi-asserted-by":"publisher","first-page":"1623957","DOI":"10.1155\/2018\/1623957","volume":"2018","author":"J Ansari","year":"2018","unstructured":"Ansari J, Ali M, Farrag A, Ali AM, Alhamad A (2018) Efficacy of Nivolumab in a patient with metastatic renal cell carcinoma and end-stage renal disease on Dialysis: case report and literature review. Case Rep Immunol 2018:1623957\u20131623954. https:\/\/doi.org\/10.1155\/2018\/1623957","journal-title":"Case Rep Immunol"},{"key":"673_CR26","doi-asserted-by":"publisher","first-page":"e14553","DOI":"10.1200\/JCO.2017.35.15_suppl.e14553","volume":"35","author":"S Park","year":"2017","unstructured":"Park S, Daniels GA (2017) Anti-PD-1 therapy in patients with end-stage renal disease on dialysis: a single-center case series. J Clin Oncol 35:e14553\u2013e14553. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.e14553","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0673-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0673-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:31:43Z","timestamp":1678559503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0673-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6,15]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0673-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"14 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was performed in humans with approval from the Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"The Institutional Review Board granted a waiver for this retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}